As DNA-PKcs is one of the most upstream key players in NHEJ [27], it is not surprising that DNA-PKcs inhibitors are more frequently tested for their potency to radiosensitize tumor cells and overcome radioresistance than DNA ligase IV inhibitors. This evidence concerns the gene PRKDC and neoplasm.